Cancer NetworkOriginal article
<![CDATA[Subcutaneous Isatuximab Enhances Patient Experience in Multiple Myeloma]]>
Phase 3positiveisatuximabPositive
AI Analysis
Summary
Phase 3 IRAKLIA trial data demonstrates that subcutaneous isatuximab delivered via on-body injector improves patient satisfaction compared to other administration routes in multiple myeloma treatment.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Patient-reported outcomes analysis showed higher satisfaction with subcutaneous isatuximab via on-body injector
Importance:6/10
Sentiment:
0.65
Phase 3Patient-Reported OutcomesMultiple MyelomaSubcutaneous AdministrationOn-Body Injector
Related Companies
Read the original article
Published by Cancer Network on September 27, 2026 3:00 PM